Business Context and Reporting Period
This Form 6-K, dated April 9, 2018, reports on a strategic transaction by Novartis AG, a Swiss-based global healthcare company. The filing announces an agreement to acquire AveXis Inc., a US-based clinical-stage gene therapy company, for a total consideration of USD 8.7 billion in cash.
Key Financial Metrics and Transaction Details
- Acquisition Price: USD 218 per share, totaling USD 8.7 billion in cash.
- Funding Source: Planned to be funded through available cash and short-term borrowing.
- Historical Context (2017): Novartis reported net sales of USD 49.1 billion and R&D expenses of approximately USD 9.0 billion.
- Projected Financial Impact:
- 2018-2019: Slightly negative impact on Core Operating Income due to R&D investments.
- 2020 and beyond: Expected to strongly contribute to Core Operating Income and Core EPS accretion driven by significant sales increases.
Material Changes and Strategic Rationale
The primary material change is the entry into a merger agreement to acquire AveXis, marking a significant expansion into gene therapy and neuroscience. Key strategic drivers include:
- Product Pipeline: Acquisition of AVXS-101, a lead gene therapy candidate for Spinal Muscular Atrophy (SMA) Type 1, which has Breakthrough Therapy designation in the US, PRIME in the EU, and Sakigake in Japan.
- Platform Value: Access to AveXis's AAV9 gene therapy manufacturing capabilities and R&D platform for other conditions like Rett Syndrome and ALS.
- Market Position: Strengthening Novartis's leadership in neuroscience and pediatric neurological diseases.
Guidance, Outlook, and Risks
Outlook and Timeline:
- Closing: Expected in mid-2018, pending tender offer success and regulatory conditions.
- Regulatory Milestones: Biologics License Application (BLA) filing with the FDA expected in H2 2018; US approval and launch expected in 2019.
- Commercial Potential: Multi-billion dollar peak sales potential for AVXS-101.
Risks and Contingencies:
- Regulatory Approval: No guarantee that AVXS-101 will receive marketing approval or be commercially successful.
- Transaction Completion: The deal is subject to customary closing conditions, including antitrust review and tender offer thresholds.
- Integration: Risks associated with integrating AveXis operations and retaining key personnel.
- Forward-Looking Statements: Actual results may vary materially due to clinical trial uncertainties, pricing pressures, and legal proceedings.
Investor Verification Checklist
- Verify the final closing date of the transaction and any changes to the USD 8.7 billion valuation.
- Monitor the FDA BLA filing status for AVXS-101 in the second half of 2018.
- Review Novartis's subsequent quarterly reports for the actual impact on Core Operating Income in 2018 and 2019.
- Assess the integration progress of AveXis's manufacturing capabilities and R&D pipeline.
- Track regulatory decisions in the EU (PRIME) and Japan (Sakigake) regarding AVXS-101.